MedTrace Logo

Intravenous Immunoglobulin for Acute Intracranial Hemorrhage

NCT02782897 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2016-05-25

No results posted yet for this study

Summary

This pilot study aims to investigate whether intravenous immunoglobulin is safe and effective in alleviating perihematomal edema and neurologic deficits in patients with intracranial hemorrhage.

Conditions

  • Intracranial Hemorrhage, Hypertensive

Interventions

DRUG

Immunoglobulin Therapy

Immunoglobulin is given intravenously 0.4 g/kg per day for five consecutive days.

OTHER

Standard management

Standard management includes: the use of mild sedation, blood pressure control, management of elevated intracranial pressure, glucose management, temperature management, airway maintenance, and management of medical complications.

Sponsors & Collaborators

  • Wei Wang

    lead OTHER

Principal Investigators

  • Wei Wang, Doctor · Tongji Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2017-12-31
Completion
2018-04-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02782897 on ClinicalTrials.gov